Clinical studies in RA patients, that determined serum markers of bone remodeling, reported beneficial effects with significantly reduced serum levels of sRANKL, an improved sRANKL/OPG ratio, and a trend of increased serum level of osteocalcin after treatment with sarilumab [16]. Here, TNFRSF11B is linked to rheumatoid arthritis.